Am J Manag Care by Trogdon, Justin G. et al.
State-Level Projections of Cancer-Related Medical Care Costs: 
2010 to 2020
Justin G. Trogdon, PhD, Florence K. L. Tangka, PhD, Donatus U. Ekwueme, PhD, Gery P. 
Guy Jr, PhD, Isaac Nwaise, PhD, and Diane Orenstein, PhD
RTI International (JGT), Research Triangle Park, NC; Division of Cancer Prevention and Control 
(FKLT, DUE, GPG), Division of Heart Disease and Stroke Prevention (IN, DO), Centers for 
Disease Control and Prevention, Atlanta, GA.
Abstract
Background—As the population ages, the financial amount spent on cancer care is expected to 
increase substantially. In this study, we projected cancer-related medical costs by state from 2010 
through 2020.
Methods—We used pooled Medical Expenditure Panel Survey data for 2004 to 2008 and US 
Census Bureau population projections to produce state-level estimates of the number of people 
treated for cancer and the average cost of their treatment, from a health system perspective, by age 
group (18-44, 45-64, ≥65 years) and sex. In the base model, we assumed that the percentage of 
people in each of the 6 age-by-sex categories who had been treated for cancer would remain 
constant and that the inflation-adjusted average cancer treatment cost per person would increase at 
the same rate as Congressional Budget Office projections of overall medical spending.
Results—We projected that state-level cancer-related medical costs would increase by 34% to 
115% (median = 72%) and that state-level costs in 2020 would range from $347 million to $28.3 
billion in 2010 dollars (median = $3.7 billion).
Conclusions—The number of people treated for cancer and the costs of their cancer-related 
medical care are projected to increase substantially for each state. Effective prevention and early 
detection strategies are needed to limit the growing burden of cancer.
Healthcare costs continue to rise nationally and impose greater burdens on state budgets.1 
Since cancer-related medical care costs constitute a substantial portion of overall US 
medical care costs,2-4 accurate projections of future cancer-related care costs are critical. 
Over the past 20 years, the cost of treating cancer has nearly doubled nationally.2,5 As a 
result of an aging population and more expensive cancer treatments, the national costs of 
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cancer care are expected to increase significantly in the near future.6 Although previous 
increases in spending on cancer have occurred despite the decreases in cancer incidence 
rates and increases in average survival times for patients with many types of cancers,7 
researchers have noted many opportunities to further improve cancer detection and treatment 
while controlling costs.8-10
To take advantage of these opportunities, state-administered insurance providers such as 
Medicaid and public healthcare providers such as the National Breast and Cervical Cancer 
Early Detection Program11 need state-level projections of future cancer care costs. Previous 
projections of cancer prevalence and cancer care costs have focused only on the national 
level.6 This study produces state-level projections of cancer care costs through 2020. While 
our goal is not to explain differences across states, our projections do reflect projected 
changes in the distribution of state residents by age and sex during this period. They provide 
a useful baseline against which to gauge the impact of current and future cancer policies and 




First, we generated estimates of the number of adults who had been treated for cancer and 
the average cost of their treatment by age group (18-44, 45-64, ≥65 years) and sex (male, 
female). The small number of children with cancer in our data prevented reliable estimates 
for children. Second, in our base projections, we assumed that the treatment rate for cancer 
in each of the 6 age-by-sex groups would remain constant and that the inflation-adjusted 
initial average cancer treatment cost per person would increase at the same rate as 
Congressional Budget Office (CBO) projections of overall medical spending.12,13 Third, we 
generated state-level projections of the total number of adults who will be treated for cancer 
and the costs of their treatment by multiplying treated cancer prevalence and average costs 
by the Census-projected population of each demographic cell. Therefore, the projections 
reflect expected changes in the distribution of state residents by sex and age group but 
assume that there will be no policy changes that could affect cancer treatment costs. For 
example, the projections do not account for possible changes in national healthcare policies 
mandated by the Affordable Care Act.
Projections of the Annual Number of US Adults Treated for Cancer
To estimate the number of adults in each state who will be treated for cancer, we used 
cancer prevalence data from the 2004 to 2008 Medical Expenditure Panel Survey (MEPS)14 
and the US Census Bureau's projections of state population counts for 2010 through 2020. 
The MEPS, a nationally representative survey of the civilian noninstitutionalized population 
administered by the Agency for Healthcare Research and Quality, provides data on 
participants’ use of medical services and on the costs of those services. MEPS provides a 
single, consistent data source to link disease prevalence and expenditures. Medical 
conditions are identified in the MEPS medical condition files; we restricted our condition 
indicators to those for which respondents received care within the interview year. Medical 
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conditions were classified using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes based on self-reported conditions that were 
transcribed by professional coders. Cancer was defined using clinical classification codes 11 
through 43 and 45, which group ICD-9-CM codes into related groups.15 We combined 
cancers of any site.
We estimated logit models for the probability of cancer treatment that controlled for survey 
year and survey participants’ age, sex, and region of residence (northeast, south, midwest, 
and west). We used stepwise regressions to identify significant interactions among these 
variables to be included in the models. The significant interactions in the stepwise 
regressions represent age-by-sex-by-region categories with enough sample and power to 
detect differences in cancer treatment rates. We estimated cancer treatment rates (ie, the 
proportion of the population treated for cancer) for US adults in each age/sex/region group 
using coefficients from the logit regressions and adjusted these estimates to account for the 
nursing home care population using data from the 2004 National Nursing Home Survey.
We used the projected state population counts for 2010 through 2020 generated in 2008 by 
the US Census Bureau on the basis of data from the 2000 Census.16 For each state, we 
multiplied the predicted percentage of people treated for cancer in each of the 6 age-by-sex 
categories by the projected number of state residents in the corresponding category for each 
year from 2010 through 2020. We then aggregated these projections to project the total 
number of people who will be treated for cancer in each state in each year.
Projections of Direct Medical Care Costs of Cancer
MEPS measures total annual medical spending, including payments by insurers and out-of-
pocket spending by patients (copayments, deductibles, and payments for noncovered 
services). The costs captured by MEPS represent payments (not charges) from the payer to 
the provider. MEPS spending data are obtained through a combination of self-reports by the 
respondents and validation of the self-reports from payers.17
We projected direct cancer-related medical care costs of cancer in 6 steps. First, we 
estimated per-person medical costs as a function of cancer by using a 2-part regression 
model (a logit model to predict the probability of any expenditure and a generalized linear 
model with a gamma distribution and a log link to estimate total annual medical 
expenditures for people having any such expenditures). To choose among alternative 
nonlinear estimators, we used an algorithm recommended by Manning and Mullahy18 and 
found the generalized linear model was the most appropriate for the data. All regressions 
included the following variables: age; age2; sex; race/ethnicity; education; family income; 
other sources of health insurance; year indicators; and indicators for cancer, arthritis, 
asthma, back problems, congestive heart failure, chronic obstructive pulmonary disease, 
coronary heart disease, depression, diabetes, dyslipidemia, human immunodeficiency virus/
acquired immunodeficiency syndrome, hypertension, injuries, other cardiovascular disease, 
other mental health/substance abuse, pneumonia, pregnancies, renal failure, skin disorders, 
and stroke.
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Second, we calculated expenditures attributable to cancer by comparing predicted 
expenditures from the 2-part regression model. To ensure no double counting of 
expenditures for co-occurring diseases, we used the “complete classification” technique 
described in an earlier study.19 We treated each disease and combination of diseases as a 
separate entity and, for each unique combination of diseases, compared predicted 
expenditures with and without the disease(s) holding all else constant. For example, we 
treated cancer alone and cancer with hyper-tension as 2 different “diseases.” We then 
divided the total expenditures attributable to the combinations of diseases back to the 
constituent diseases using the parameters from the model to construct shares for each 
constituent disease within a combination (ie, a share of all cancer with hypertension disease 
costs that are attributable to cancer). The shares attribute a greater share of the joint 
expenditures to the disease with the larger coefficient in the main effect.19 We estimated 
per-person costs attributable to cancer for each age/sex/region category on the basis of 
coefficients from the national model.
Third, we used the 2004 National Nursing Home Survey and National Health Accounts to 
adjust our per-person cost estimates to account for nursing home spending. We assumed that 
average per-person, non-nursing home expenditures attributable to cancer were the same for 
the nursing home population as for the non-institutionalized population.
Fourth, we used confidential MEPS data that identified the most populous 30 states and 9 
Census divisions to generate state-specific per-person cost estimates. Sample sizes were not 
large enough for us to replicate the full analysis for each state. We regressed log (positive) 
medical expenditures on the variables in the model plus state/census division dummies. The 
coefficients on the dummies provided measures of the differences in average medical care 
costs across states that we used to scale the national estimates to make them state-specific.
Fifth, we estimated future costs by inflating dollar values in the MEPS data to the equivalent 
of 2010 values in accordance with recommendations from the Agency for Healthcare 
Research and Quality20 and then multiplied the projected per-person cost of cancer for 
people in each age/sex/state category by the number of people in the corresponding category 
that we projected will be treated for cancer in 2010 and in 2020. We then added the 
projections for each category to estimate total annual costs of cancer care.
Finally, we adjusted our cost projections on the basis of CBO assumptions that future 
healthcare costs not attributable to population growth and aging will increase by an average 
annual rate of 3.6% between 2010 and 2020.12,13
Sensitivity Analysis
We generated four 10-year projections of cancer care costs using the following assumptions 
about future US cancer prevalence rates: 1) no change in cancer incidence or survival rates 
(base projections), 2) continued trends in cancer incidence rates, 3) continued trends in 
cancer survival rates, and 4) continued trends in both incidence and survival rates. Incidence 
trends represent changes due to prevention and risk factor prevalence, and survival trends 
represent changes in early detection and treatment. We used trends in incidence and survival 
reported by Mariotto et al.6
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First, using Census projections for the year 2020, we converted their estimates of the 
number of cancer survivors for all sites under the 4 modeling assumptions6(Table 3) to the 
implied cancer prevalence rates in each model. Second, we calculated the percentage 
difference in the predicted 2020 prevalence rates between the 3 alternative models and the 
base model. The differences between the alternative models and the base model hold the 
2020 population constant and reflect differences due to the alternative assumptions. Third, 
we applied the percentage differences in 2020 prevalence rates between each of the 3 
alternative assumptions and the base model at the national level to each of our age/sex/state 
categories in the year 2020. For years 2010 to 2020, we assumed linear growth from the 
2010 value to the 2020 value by age, sex, and state.
We also generated cancer medical care cost projections using alternative assumptions of 
medical cost growth. Our baseline assumption was that per-person costs of cancer grew at 
the historical rate of growth of overall medical spending, 3.6% per year.13 In the sensitivity 
analysis, we applied the following growth rates to per-person cancer costs: 0%, 2%, and 
5%.6
RESULTS
In the base model, projected state-level changes in the number of residents treated for cancer 
between 2010 and 2020 ranged from −7% in the District of Columbia to 46% in Arizona 
(median = 17%; data not shown). The states with the largest projected increases in the 
number of people treated for cancer were Florida (353,000), California (351,000), and Texas 
(249,000). Projected percentage increases in cancer care costs between 2010 and 2020 
ranged from 34% in the District of Columbia to 115% in Arizona (median = 72%) (Table 1). 
Projected actual increases in costs ranged from $347 million in the District of Columbia to 
$28.3 billion in California (median, $3.7 billion) (Figure 1).
Our projections of cancer-related medical costs were not sensitive to alternative assumptions 
about future cancer incidence and survival rates (Table 2). Accounting for trends in cancer 
incidence rates,6 projected medical costs were 3% lower than in the base model. Accounting 
for trends in cancer survival rates,6 projected medical costs were 10% higher than in the 
base model. However, accounting for both of these assumptions simultaneously, projected 
medical care costs were only 1% higher than in the base model.
Compared with our base model, projections based on the assumption of 0% increase in per 
capita medical care costs were 34% lower and those based on the assumption of 5% growth 
were 18% higher. Changes from 2010 to 2020 in projected state-level cancer care costs 
derived from the 0% cost-growth model, in which we assumed no change in treated cancer 
prevalence or inflation-adjusted per capita medical care costs, reflect solely the impact of 
projected changes in state populations and in the age and sex distribution of state residents 
(Figure 2). The combined impact of these 2 factors on projected changes in cancer-related 
medical costs between 2010 and 2020 ranged from a 12% decrease for the District of 
Columbia to a 41% increase for Arizona (median = 13% increase).
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Our base model, which assumed no change in the cancer treatment rate and a 3.6% annual 
increase in inflation-adjusted per capita medical costs, showed that the state-level percentage 
change in the annual number of cancer cases treated between 2010 and 2020 will range from 
−7% to 46% (median = 17%; data not shown) across states and that the state-level 
percentage increase in cancer-related medical costs will range from 34% to 115% (median = 
72%). Our projections of state-level percentage increases in the number of treated cancer 
cases between 2010 and 2020 varied significantly across states and closely paralleled 
projected increases in the number of residents 65 years or older. States with the largest 
projected percentage increases in number of residents 65 years or older also had the largest 
projected percentage increases in cancer-related medical costs.16
Accounting for a declining trend in the US cancer incidence rate and an increasing trend in 
the US cancer survival rate had little net effect on our cost projections. However, cost 
projections were sensitive to changes in assumptions about the annual rate of change in 
medical costs. Compared with projections derived from our base model (3.6% annual 
increase), projections based on assumptions of 0% cost growth and 5% cost growth were 
34% lower and 18% higher, respectively. Projections derived from the 0% cost-growth 
model are interesting for at least 2 reasons: 1) they show the impact that population growth 
and aging will likely have on state cancer-related medical costs, and 2) given that recent 
evidence suggests that the average inflation-adjusted per-person cost of cancer treatment did 
not change much from 1987 to 2005,2 projections of state-level cancer-related medical costs 
derived from this model may be more accurate than those derived from our base model. 
However, the relatively flat per-person cost of cancer treatment over this period was driven 
mainly by cancer treatment being provided more frequently in outpatient settings.2 Unless 
this trend continues, we should expect future per-person cancer treatment costs to increase at 
a higher rate.
In a recent national-level projection of US cancer care costs based on assumptions of 0% 
cost growth and no change in cancer incidence or survival rates, Mariotto and colleagues 
estimated that costs would increase by 27% between 2010 and 2020,6 which was 
substantially higher than the average projected increase in cancer treatment costs in our 
study (15%). This difference is likely attributable to differences in the data sources used in 
the 2 studies. Mariotto and colleagues,6 used Surveillance Epidemiology and End Results-
Medicare files, which provide clinical registry data about cancer prevalence linked to 
Medicare payments. However, because Medicare covers only people 65 years or older, 
Mariotto and colleagues, had to extrapolate these data to people younger than 65 years. In 
contrast, we used MEPS data, which were collected from self-reports of a cross section of 
US adults.
Limitations
MEPS has at least 4 limitations that may have affected our projections: 1) it is subject to 
sampling error; 2) participants’ reports of their cancer status were not verified by chart 
review; 3) its small sample sizes precluded us from stratifying our projections of cancer 
Trogdon et al. Page 6













costs by type of cancer or cancer stage; and 4) institutionalized populations were not 
sampled. We adjusted estimates to account for nursing home populations.
In addition, the accuracy of our projections is dependent on the accuracy of the many 
assumptions on which the projections were based. For example, we assumed that the initial 
prognosis of cancer patients would not change. To the extent that the percentage of cancer 
patients who adhere to recommended treatments increases, or new life-prolonging 
technologies are developed, cancer patients will live longer and the prevalence of cancer 
will be higher than we projected. Conversely, if the incidence of cancer at different sites 
increases or decreases, the number of people treated for cancer and cancer treatment costs 
could be either greater or less than we projected. In addition, the accuracy of our cost growth 
assumption could be affected by changes in the rate of investment in new cancer 
technologies or in the relative proportion of different cancer types.
Due to the number of data sources that were combined for the estimates, it was not possible 
to generate standard errors for the cost projections. The relative standard error (ie, standard 
error as a percentage of the estimate) for the estimate of treated cancer prevalence in MEPS 
was 8%. The relative standard error for the estimates of the per-person medical cost was 
11%.
Finally, our projections do not reflect the true overall costs of cancer, which, in addition to 
medical treatment costs, also include patients’ nonmedical costs for travel and child care, the 
costs of lost productivity, costs incurred by unpaid caretakers of cancer patients, and 
intangible costs associated with psychological pain and stress experienced by cancer patients 
and their families.21,22 Even though medical costs are often the sole focus of economic 
research and debate concerning proposed policy changes affecting cancer patients, 
participants in such research and debate should also consider nonmedical costs.
CONCLUSIONS
We project that the cost of medical care for cancer patients will increase substantially 
through 2020 in all US states but that the rate of increase will vary by state. We hope that 
states find these projections useful as they try to make evidence-based decisions about the 
allocation of resources for cancer research and interventions as well as other policy 
decisions related to cancer prevention and treatment. These projections also provide a useful 
baseline against which to gauge the impact of current and future cancer policies.
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■ We project that the cost of medical care for cancer patients will increase 
substantially through the year 2020 in all US states.
■ Effective prevention and early detection strategies are needed to limit the growing 
burden of cancer.
■ These estimates provide a useful baseline against which to gauge the impact of 
current and future cancer policies.
■ These estimates could be useful for budget allocations for investments in cancer 
prevention and early detection.
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Projected State Costs of Cancer Care in 2020
Estimates of state expenditures for cancer care in 2020 are based on the assumptions that the 
percentage of people treated for cancer remains constant within age, sex, and state categories 
but that state population counts and population distributions by age and sex will change as 
projected by the Census and that the inflation-adjusted cost of cancer care per person will 
increase by 3.6% per year. Costs in 2010 million US dollars. Color-coded categories 
represent quintiles.
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Projected Increase in State Costs of Cancer Care Between 2010 and 2020
Estimates of state expenditures for cancer care in 2010 (white) and the estimated increase in 
these expenditures between 2010 and 2020 (blue) are based on assumptions that the 
percentage of people treated for cancer remains constant within age, sex, and state 
categories; that the inflation-adjusted cost of cancer care is unchanged; and that state 
populations and the population distributions by age and sex will change as projected by the 
Census. Costs in 2010 billion US dollars.
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Table 1
Projected State Costs of Cancer Care in 2010 US Dollars
State 2010, Million $ 2015, Million $ 2020, Million $ % Change 2010 to 2020
Alabama 2527 3289 4279 69
Alaska 261 366 508 95
Arizona 2981 4363 6402 115
Arkansas 1394 1816 2366 70
California 15,532 21,041 28,331 82
Colorado 2368 3211 4322 83
Connecticut 2252 2897 3686 64
Delaware 518 703 943 82
District of Columbia 259 300 347 34
Florida 12,742 17,723 24,948 96
Georgia 3926 5371 7260 85
Hawaii 734 978 1,291 76
Idaho 732 1008 1398 91
Illinois 5969 7627 9771 64
Indiana 3060 3927 5055 65
Iowa 1572 1993 2556 63
Kansas 1329 1706 2215 67
Kentucky 2228 2900 3775 69
Louisiana 2124 2751 3573 68
Maine 793 1060 1404 77
Maryland 2781 3675 4792 72
Massachusetts 3702 4793 6174 67
Michigan 5505 7116 9193 67
Minnesota 2507 3310 4400 75
Mississippi 1322 1725 2259 71
Missouri 2676 3456 4482 67
Montana 570 769 1048 84
Nebraska 857 1096 1416 65
Nevada 1330 1952 2821 112
New Hampshire 701 957 1292 84
New Jersey 5169 6707 8643 67
New Mexico 1096 1516 2077 90
New York 10,778 13,780 17,456 62
North Carolina 4635 6279 8462 83
North Dakota 337 430 560 66
Ohio 5316 6779 8656 63
Oklahoma 1857 2380 3068 65
Oregon 1992 2680 3623 82
Pennsylvania 7567 9587 12,216 61
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State 2010, Million $ 2015, Million $ 2020, Million $ % Change 2010 to 2020
Rhode Island 594 761 976 64
South Carolina 2334 3175 4276 83
South Dakota 399 514 672 68
Tennessee 3650 4858 6422 76
Texas 10,516 14,384 19,686 87
Utah 977 1334 1849 89
Vermont 357 484 650 82
Virginia 4142 5608 7497 81
Washington 3273 4463 6081 86
West Virginia 1181 1513 1941 64
Wisconsin 3057 3999 5262 72
Wyoming 290 394 539 86
Median 2228 2897 3686 72
Note: Cost projections were based on the following assumptions: 1) the annual percentage of state residents treated for cancer will remain constant 
within age and sex categories; 2) the distribution of state residents by sex and age group will change as projected by the Census; 3) annual medical 
care costs will increase by 3.6% (in inflation-adjusted 2010 dollars).
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Table 2
Projected State Costs of Cancer Care Based on 4 Sets of Assumptions About Future Cancer Incidence Rates, 
Cancer Survival Rates, and Annual Increases in the Cost of Medical Care
Projected State-Level Costs of Cancer Care in 2010 US Dollars (Millions), by Assumptions Used
2010 2020
State Base Base Trend Incidence Trend Survival Trend Incidence and 
Survival
Under Base: Cost Increase
0% 2% 5%
Alabama 2527 4279 4135 4706 4316 2807 3560 5041
Alaska 261 508 491 559 512 333 422 598
Arizona 2981 6402 6187 7042 6457 4200 5326 7542
Arkansas 1394 2366 2286 2602 2386 1552 1968 2787
California 15,532 28,331 27,382 31,164 28,577 18,586 23,571 33,377
Colorado 2368 4322 4178 4755 4360 2836 3596 5092
Connecticut 2252 3686 3562 4054 3718 2418 3066 4342
Delaware 518 943 911 1037 951 618 784 1111
District of Columbia 259 347 336 382 350 228 289 409
Florida 12,742 24,948 24,112 27,443 25,165 16,367 20,757 29,392
Georgia 3926 7260 7017 7986 7323 4763 6040 8553
Hawaii 734 1291 1248 1420 1302 847 1074 1521
Idaho 732 1398 1351 1538 1410 917 1163 1647
Illinois 5969 9771 9443 10,748 9856 6410 8129 11,511
Indiana 3060 5055 4886 5561 5099 3316 4206 5956
Iowa 1572 2556 2471 2812 2579 1677 2127 3012
Kansas 1329 2215 2141 2437 2234 1453 1843 2610
Kentucky 2228 3775 3648 4152 3808 2476 3141 4447
Louisiana 2124 3573 3454 3931 3605 2344 2973 4210
Maine 793 1404 1357 1545 1417 921 1168 1655
Maryland 2781 4792 4631 5271 4834 3144 3987 5646
Massachusetts 3702 6174 5967 6791 6227 4050 5136 7273
Michigan 5505 9193 8885 10,112 9273 6031 7648 10,830
Minnesota 2507 4400 4253 4840 4438 2887 3661 5184
Mississippi 1322 2259 2183 2485 2278 1482 1879 2661
Missouri 2676 4482 4332 4930 4521 2940 3729 5280
Montana 570 1048 1013 1153 1057 687 872 1234
Nebraska 857 1416 1368 1557 1428 929 1178 1668
Nevada 1330 2821 2726 3103 2845 1851 2347 3323
New Hampshire 701 1292 1248 1421 1303 847 1075 1522
New Jersey 5169 8643 8353 9507 8718 5670 7191 10,182
New Mexico 1096 2077 2007 2285 2095 1363 1728 2447
New York 10,778 17,456 16,871 19,202 17,608 11,452 14,523 20,565
North Carolina 4635 8462 8178 9308 8535 5551 7040 9969
North Dakota 337 560 541 616 564 367 466 659
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Projected State-Level Costs of Cancer Care in 2010 US Dollars (Millions), by Assumptions Used
2010 2020
State Base Base Trend Incidence Trend Survival Trend Incidence and 
Survival
Under Base: Cost Increase
0% 2% 5%
Ohio 5316 8656 8366 9522 8731 5678 7202 10,198
Oklahoma 1857 3068 2965 3375 3095 2013 2553 3614
Oregon 1992 3623 3502 3985 3654 2377 3014 4268
Pennsylvania 7567 12,216 11,807 13,438 12,322 8014 10,164 14,392
Rhode Island 594 976 943 1073 984 640 812 1150
South Carolina 2334 4276 4133 4703 4313 2805 3558 5037
South Dakota 399 672 650 740 678 441 559 792
Tennessee 3650 6422 6207 7064 6478 4213 5343 7566
Texas 10,516 19,686 19,027 21,655 19,857 12,914 16,379 23,193
Utah 977 1849 1787 2034 1865 1213 1538 2178
Vermont 357 650 628 715 656 426 541 766
Virginia 4142 7497 7246 8247 7562 4918 6237 8832
Washington 3273 6081 5878 6690 6134 3990 5060 7165
West Virginia 1181 1941 1876 2135 1958 1273 1615 2287
Wisconsin 3057 5262 5086 5789 5308 3452 4378 6200
Wyoming 290 539 521 593 544 354 449 635
Median 2228 3686 3562 4054 3718 2418 3066 4342
Note: Cost projections under the base scenario were based on the following assumptions: 1) the annual percentage of state residents treated for 
cancer will remain constant within age and sex categories; 2) the distribution of state residents by sex and age groups will change as projected by 
the Census; 3) annual medical care costs will increase by 3.6% (in inflation-adjusted 2010 dollars). Incidence trend and survival trend cost 
projections are based on assumptions that trends in cancer survival and cancer incidence rates will continue as modeled by Mariotto and 
colleagues.6 Specifically, the implied difference in 2020 all-site prevalence between the base scenario and the alternative prevalence scenarios in 
Mariotto and colleagues6 was applied to the treated prevalence estimates by age, sex, and state categories. Cost scenarios were 0%, 2%, and 5% 
annual increases in real costs per person starting in 2008, the last year of source data.
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